FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033389750> ?p ?o ?g. }

• W2033389750 endingPage "32" @default.
• W2033389750 startingPage "21" @default.
• W2033389750 abstract "Inhibitors of the inflammatory cytokine tumor necrosis factor (TNF) have proven to be highly effective in the treatment of various autoimmune conditions, including rheumatoid arthritis (RA). Indeed, according to several international guidelines that were based upon abundant evidence from therapeutic trials and clinical experience, these agents have come to be considered a cornerstone of therapy for RA patients with severe or refractory disease (1, 2) However, in addition to its central role in the immune driven systemic inflammation of RA, TNF is also important to immunologic surveillance. Because of the key role that the immune system plays in host defense, there is concern that therapy with TNF inhibitors (TNFi) might predispose patients to adverse effects related to impaired immunity, including an increased incidence of infections and/or cancer. Despite many years of clinical research and more than a decade since the introduction of TNF inhibitors into the clinic, there is disagreement about the potential association between use of these agents and malignancy.From a mechanistic standpoint, it could be hypothesized that inhibition of TNF could either enhance or inhibit cancer development (3–6). On the one hand, via mechanisms such as induction of apoptosis or suppressive effects on gene expression, TNF may suppress the development of certain tumors (5). Indeed, the name ‘TNF’, which was coined well before the role of this cytokine in inflammation and in numerous autoimmune diseases was known, reflects the observed inhibitory effects of this cytokine on certain tumors. Therefore, blockade of TNF may enhance the risk of cancer. In addition, TNF serves as a key element of the inflammatory response whose inhibition may increase the risk to various infections. This could potentially place the host at greater risk of cancers driven by chronic infections, particularly viral (7). By these mechanisms, inhibiting TNF might increase the risk of cancer. On the other hand, uncontrolled inflammation itself may also potentiate cancer (3, 4). Also, among the myriad activities of TNF is its profound effect on angiogenesis, which is critical to tumor growth, survival, and metastasis (3, 4). Therefore, potent anti-inflammatory treatments, such as TNFi, could decrease the risk of cancer through suppressing inflammation and reducing angiogenesis. This concept is supported by two lines of data. First, patients with higher levels of systemic inflammation, such as those with RA, are at a greater risk for developing lymphomas (8). Second, treatment with corticosteroids, which possess diverse anti-inflammatory properties, appear to be associated with a lesser risk of lymphoma development (9).Similar to the basic science suggesting that TNFi may increase or decrease the risk of cancer, randomized controlled trials do not provide definitive evidence about this relationship. Two recent meta-analyses found no clear evidence of increased cancer risk with the use of TNFi. (10, 11). One large meta-analysis that included only the monoclonal antibodies, infliximab and adalimumab, found an increased risk of cancer (12). A meta-analysis focused on etanercept suggested a trend toward an increased risk but the confidence interval spanned one for the primary analysis and secondary analyses did not all suggest increased cancer risk (13). Furthermore, a study of patients enrolled in adalimumab trials for early RA found no significant increase in cancer risk (14). While randomized controlled trials are the gold standard for efficacy, they may not provide the best information regarding a drug’s toxicity, owing to their relatively short duration and strict inclusion criteria that may exclude important at-risk groups (15). Epidemiologic studies of patients in typical care allows for analysis of more relevant subjects with a variety of comorbid conditions using concomitant treatments.With this background, we undertook a systematic review of epidemiologic studies of the relationship between TNFi and cancer. Prior reviews have examined this risk of cancer in RA (16). Whereas, this review focuses on both the methodologic attributes of studies examining TNFi and cancer, as well as their results. We did not attempt a meta-analysis because of the obvious methodological heterogeneity and opted to present the findings as a systematic review, as suggested by the Cochrane Collaboration (17)." @default.
• W2033389750 created "2016-06-24" @default.
• W2033389750 creator A5041948290 @default.
• W2033389750 creator A5050398307 @default.
• W2033389750 creator A5058110978 @default.
• W2033389750 date "2011-12-29" @default.
• W2033389750 modified "2023-10-16" @default.
• W2033389750 title "Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: A review of their methodologies and results" @default.
• W2033389750 cites W1977434336 @default.
• W2033389750 cites W1986109277 @default.
• W2033389750 cites W1992746042 @default.
• W2033389750 cites W1992934058 @default.
• W2033389750 cites W1995515383 @default.
• W2033389750 cites W2007400424 @default.
• W2033389750 cites W2009928292 @default.
• W2033389750 cites W2012612087 @default.
• W2033389750 cites W2013627195 @default.
• W2033389750 cites W2014415089 @default.
• W2033389750 cites W2017281030 @default.
• W2033389750 cites W2017497764 @default.
• W2033389750 cites W2028672514 @default.
• W2033389750 cites W2045789990 @default.
• W2033389750 cites W2050182784 @default.
• W2033389750 cites W2055176162 @default.
• W2033389750 cites W2062694326 @default.
• W2033389750 cites W2069954767 @default.
• W2033389750 cites W2071099746 @default.
• W2033389750 cites W2089548173 @default.
• W2033389750 cites W2102213888 @default.
• W2033389750 cites W2104388056 @default.
• W2033389750 cites W2106249804 @default.
• W2033389750 cites W2116048670 @default.
• W2033389750 cites W2118278569 @default.
• W2033389750 cites W2125657144 @default.
• W2033389750 cites W2131882149 @default.
• W2033389750 cites W2133435333 @default.
• W2033389750 cites W2133439754 @default.
• W2033389750 cites W2144015200 @default.
• W2033389750 cites W2147648627 @default.
• W2033389750 cites W2154986972 @default.
• W2033389750 cites W2158911776 @default.
• W2033389750 cites W2159728707 @default.
• W2033389750 cites W2160648494 @default.
• W2033389750 cites W2164595809 @default.
• W2033389750 cites W2166732840 @default.
• W2033389750 cites W2169666959 @default.
• W2033389750 cites W4297409492 @default.
• W2033389750 doi "https://doi.org/10.1002/art.30653" @default.
• W2033389750 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3241884" @default.
• W2033389750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21898354" @default.
• W2033389750 hasPublicationYear "2011" @default.
• W2033389750 type Work @default.
• W2033389750 sameAs 2033389750 @default.
• W2033389750 citedByCount "59" @default.
• W2033389750 countsByYear W20333897502012 @default.
• W2033389750 countsByYear W20333897502013 @default.
• W2033389750 countsByYear W20333897502014 @default.
• W2033389750 countsByYear W20333897502015 @default.
• W2033389750 countsByYear W20333897502016 @default.
• W2033389750 countsByYear W20333897502017 @default.
• W2033389750 countsByYear W20333897502018 @default.
• W2033389750 countsByYear W20333897502019 @default.
• W2033389750 countsByYear W20333897502020 @default.
• W2033389750 countsByYear W20333897502021 @default.
• W2033389750 countsByYear W20333897502022 @default.
• W2033389750 countsByYear W20333897502023 @default.
• W2033389750 crossrefType "journal-article" @default.
• W2033389750 hasAuthorship W2033389750A5041948290 @default.
• W2033389750 hasAuthorship W2033389750A5050398307 @default.
• W2033389750 hasAuthorship W2033389750A5058110978 @default.
• W2033389750 hasBestOaLocation W20333897501 @default.
• W2033389750 hasConcept C121608353 @default.
• W2033389750 hasConcept C126322002 @default.
• W2033389750 hasConcept C143998085 @default.
• W2033389750 hasConcept C17991360 @default.
• W2033389750 hasConcept C23131810 @default.
• W2033389750 hasConcept C2777575956 @default.
• W2033389750 hasConcept C3020084786 @default.
• W2033389750 hasConcept C71924100 @default.
• W2033389750 hasConceptScore W2033389750C121608353 @default.
• W2033389750 hasConceptScore W2033389750C126322002 @default.
• W2033389750 hasConceptScore W2033389750C143998085 @default.
• W2033389750 hasConceptScore W2033389750C17991360 @default.
• W2033389750 hasConceptScore W2033389750C23131810 @default.
• W2033389750 hasConceptScore W2033389750C2777575956 @default.
• W2033389750 hasConceptScore W2033389750C3020084786 @default.
• W2033389750 hasConceptScore W2033389750C71924100 @default.
• W2033389750 hasIssue "1" @default.
• W2033389750 hasLocation W20333897501 @default.
• W2033389750 hasLocation W20333897502 @default.
• W2033389750 hasLocation W20333897503 @default.
• W2033389750 hasLocation W20333897504 @default.
• W2033389750 hasOpenAccess W2033389750 @default.
• W2033389750 hasPrimaryLocation W20333897501 @default.
• W2033389750 hasRelatedWork W1965275883 @default.
• W2033389750 hasRelatedWork W1972750249 @default.
• W2033389750 hasRelatedWork W2004851027 @default.
• W2033389750 hasRelatedWork W2031283019 @default.

• next